Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 9Terminated 5Withdrawn 2Unknown 2Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 62Gastrointestinal 46Genitourinary 23Breast 18Gynecologic 12Head & Neck 11Dermatologic 6Sarcoma 5Tumor-Agnostic 3Other solid neoplasm 3CNS 2Other hematologic neoplasm 1Lymphoid 1

Conditions

Sezary Syndrome 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1

Interventions

Rituximab 129Cyclophosphamide 122Doxorubicin 62Vincristine 61venetoclax 59Prednisone 57ibrutinib 52Specimen Handling 50fludarabine 47Lenalidomide 47Biopsy 46obinutuzumab 44acalabrutinib 43Etoposide 41fludarabine phosphate 36Magnetic Resonance Spectroscopy 36Cytarabine 35CT-P10 35Dexamethasone 34Methotrexate 29Bendamustine Hydrochloride 27pembrolizumab 26Nivolumab 22blinatumomab 21zanubrutinib 20prednylidene 19Calcium Dobesilate 19deltacortene 18Radiotherapy 18Melphalan 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × durvalumab × Lymphoid × Clear all
NCT03011814 2025-09-18

Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma

City of Hope Medical Center

Phase 1/2 Active not recruiting
38 enrolled
DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡